Non-small Cell Lung Cancers
Oncology
Prevalence
30.0 / 100K
1 drug in development·1 company·3 clinical trials
Drug Pipeline by Phase
Phase 1(1)
| Drug | Company |
|---|---|
| xmt-2056 | Mersana Therapeutics, Inc. (MRSN) |
Frequently asked questions
How many drugs are in development for Non-small Cell Lung Cancers?
BioSniper tracks 1 drug in development for Non-small Cell Lung Cancers across 1 company.
How many clinical trials target Non-small Cell Lung Cancers?
There are 3 clinical trials targeting Non-small Cell Lung Cancers tracked by BioSniper.
What is the prevalence of Non-small Cell Lung Cancers?
The estimated prevalence of Non-small Cell Lung Cancers is approximately 30.0 per 100,000 population.
Deep-dive into Non-small Cell Lung Cancers
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis